Recent news on Rituximab

Wilmot Cancer Center Scientist gets $1.5M to Advance Lymphoma Research  -  25 May 2007
PressZoom (press release),Rituximab, also known as Rituxan, is effective in treating the disease, but how it actually works remains unclear to scientists and oncologists.

Genta Incorporated to Present Multiple Abstracts at the Annual ...  -  25 May 2007
Earthtimes.orgGaRD Study: Gallium, Rituximab, and Dexamethasone for Relapsed NHL. Poster #Y1, Abstract #8079; Saturday, June 2, 2007. -- Oblimersen (Genasense(R)) Can Be

Rochester Business Journal  -  May 23, 2007
Rochester Business Journal,Rituximab, also known as Rituxan, is effective in treating the disease, but its working remains unclear to scientists and oncologists.

AAN: Rituximab Reduces MS Lesions and Relapses  -  May 2, 2007
MedPage Today,BOSTON, May 2 -- Six months of rituximab (Rituxan) for relapsing-remitting multiple sclerosis lesions appears to reduce active lesions significantly and

Rituximab reduces disease activity in multiple sclerosis  -  May 2, 2007
News-Medical.net,By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses,

Biogen Idec/Genentech: Promising phase II data for rituximab in MS  -  May 1, 2007
Pharmaceutical Business ReviewLong term safety data from the upcoming phase III studies of rituximab will be essential to discern any links to serious adverse events.

Adding rituximab improves response in cyclophosphamide-resistant lupus  -  May 1, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Patients with cyclophosphamide-resistant proliferative lupus nephritis show a clinical and histological response when rituximab

Chemotherapy With Rituximab Is Better For Indolent Lymphoma Patients  -  May 2, 2007
Medical News Today (press release),Patients with indolent or mantle cell lymphoma have higher overall survival rates when given the antibody rituximab in addition to their standard

Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment ...  -  May 17, 2007
PharmaLive.com (press release),The PIX303 trial will examine the time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the

Market Report -- In Play (GTOP)  -  May 21, 2007
MSN MoneyGenitope initiates clinical trial to evaluate use of MyVax Personalized Immunotherapy following treatment with Rituximab and Chemotherapy Co announces the

Pixantrone Granted Fast Track Designation By FDA For Relapsed ...  -  May 8, 2007
Medical News Today (press release),The FDA also noted that the proposed phase III trial in combination with fludarabine and rituximab "has the potential to demonstrate an effect on a serious

Analysis: Cancer drug slows MS  -  May 1, 2007
United Press InternationalResearchers said Tuesday the anti-cancer drug rituximab -- sold as Rituxan -- that degrades part of the immune system, reduced by 90 percent signs of

Multiple Sclerosis Awareness Month  -  May 3, 2007
HULIQ,Treatment with the drug rituximab significantly reduced the number of new brain lesions and the frequency of relapses, times when symptoms of MS flare up.

Indian drug maker cuts cost of cancer therapy  -  May 1, 2007
International Herald Tribune,Rituximab treats non-Hodgkin's lymphoma, a blood malignancy. Reddy's released Reditux over the weekend in Hyderabad, India, where the company is based.

Oxford hospital’s software innovation set to revolutionise ...  -  May 22, 2007
Healthcare RepublicRituximab, in combination with methotrexate, is indicated for the treatment of adult patients with severe active RA who have had an inadequate response or

Point Therapeutics Reports First Quarter 2007 Financial Results  -  May 10, 2007
PharmaLive.com (press release),Development Grant which funded a portion of the Company's Phase 2 study combining talabostat with rituximab in advanced chronic lymphocytic leukemia.

Pixantrone Granted Fast Track Status for Treating Relapsed ...  -  May 8, 2007
Facts and Comparisons,Pixantrone in combination with fludarabine and rituximab is being investigated to determine its effects on the time to disease progression in patients with

Dr. Reddy's launches Reditux(TM)  -  May 1, 2007
Andhra Cafe,Hyderabad: Dr Reddy’s Laboratories announced the launch of Reditux(TM), the Dr Reddy’s brand of rituximab, a monoclonal antibody (MAb) used in the treatment

Talabostat Clinical Program Put on Clinical Hold by FDA  -  May 22, 2007
PipelineReview.com (press release),...in combination with rituximab in advanced chronic lymphocytic leukemia and in combination with gemcitabine in Stage IV pancreatic cancer.

Dr. Reddy’s launches Reditux(TM) Monoclonal Antibody Treatment for ...  -  Apr 30, 2007
PipelineReview.com (press release),Dr Reddy’s Laboratories (NYSE: RDY) today announced the launch of Reditux(TM), the Dr Reddy’s brand of rituximab, a monoclonal antibody (MAb) used in the

Pharma firms see gains in niche areas  -  May 13, 2007
Times of India,Recently, Dr Reddy's has launched a generic version of Roche's biologic blockbuster Rituxan (rituximab), a monoclonal antibody (MAb) for the treatment of

Knocking Out Survival Protein Could Aid Leukemia Treatment  -  26 Apr 2007
Medical News Today (press release),Cells with an overabundance of the protein are also more resistant to anticancer drugs such as rituximab, which has revolutionized the treatment of certain

Rochester Physician Helps Lead Approach Against Lupus  -  26 Apr 2007
Media Newswire (press release),The research with rituximab is some of the most exciting research going on in lupus, which affects roughly 1 million people in the United States.

Intraventricular Rituximab Safe in Recurrent CNS Lymphoma  -  Apr 24, 2007
Cancerpage.com,NEW YORK APR 24, 2007 (Reuters Health) - Initial data indicate that intraventricular administration of rituximab is a useful approach in patients with

Immunology: Pimp my antibody  -  Apr 25, 2007
Nature.com (subscription),It took the blockbuster success of drugs such as rituximab — the first antibody approved to treat cancer in 1997, developed by Genentech and IDEC

Knocking out Mcl1 protein could aid leukemia treatment  -  Apr 22, 2007
News-Medical.net,Cells with an overabundance of the protein are also more resistant to anticancer drugs such as rituximab, which has revolutionized the treatment of certain

Survival protein that aids leukaemia identified  -  Apr 21, 2007
DailyIndia.com,These results give us a rationale for lowering the amount of this protein in CLL cells and suggest that this should enhance the action of rituximab and

“Oldâ€? Monoclonal Antibody May Offer “Newâ€? Alternative  -  Apr 17, 2007
Newswise (press release)To identify the mechanisms of resistance to rituximab and improve the therapeutic efficacy of this immunotherapy in patients with non-hodgkin’s lymphoma

Cell Therapeutics, Inc. (CTI) Files for Special Protocol ...  -  Apr 4, 2007
Drug Newswire (press release),Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients with relapsed indolent NHL

ProNAi Announces Preclinical Success for PNT2258 Therapeutic ...  -  Apr 18, 2007
PipelineReview.com (press release),He added, “However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating

90 Minute Infusion of Rituxan® Well Tolerated  -  Apr 16, 2007
Cancer Consultants (press release),Researchers from Canada have reported that a 90 minute infusion of Rituxan (rituximab) is safe with resultant decrease in time and resource utilization.

Knocking Out Survival Protein Could Aid Leukemia Treatment  -  Apr 21, 2007
Cancer Focus,An effective way to fight leukemiaterm might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

‘My life is in PCT’s hands’  -  Apr 6, 2007
Wimbledon Guardian,A top consultant at the Royal Marsden Hospital recommended a combination of three drugs, including Rituximab, to treat him.

Fred Thompson, GOP Potential Candidate, Had Rare NHL  -  Apr 11, 2007
MedPage Today,Thompson was treated with radiation and rituximab (Rituxan). Since then, Dr. Cheson said, non-invasive scans have found no evidence of disease in Thompson,

Former Sen. Fred Thompson Has Marginal Zone Lymphoma  -  Apr 11, 2007
ScienceBlogsToday possible presidential candidate Fred Thompson revealed that he has been treated with the anti-CD-20 monoclonal antibody rituximab for a marginal zone

Genentech financially strong while Amgen struggles  -  Apr 13, 2007
BiopharmaReporter.com,Genentech said strong sales of cancer drugs Avastin and Rituxan (Rituximab) were the main growth drivers in the quarter results.

Roche expands antibody presence with THP purchase  -  Apr 2, 2007
DrugResearcher.com,This was mainly due to the success of their collaborative oncology drugs, Rituxan (rituximab) Herceptin (Trastuzumab) and Avastin (bevacizumab).

Survival protein boosting leukemia cells  -  Apr 20, 2007
Science Daily (press release)Cells with an overabundance of the protein are also more resistant to anti-cancer drugs such as rituximab, which has revolutionized the treatment of certain

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ...  -  Apr 19, 2007
PipelineReview.com (press release),...myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab.

Anadys Pharmaceuticals presents data showing ANA773 promotes anti ...  -  Apr 18, 2007
News-Medical.net,This study showed that transformed B cells, targeted by addition of the anti-CD20 antibody rituximab, were killed more efficiently when PBMC containing the

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC ...  -  Apr 18, 2007
PharmaLive.com (press release),New drug or biological candidates targeting B-cells, including the recently approved rituximab (Rituxan(R)) for lymphomas and rheumatoid arthritis,

Pipeline Insight: Disease Modification in Rheumatoid Arthritis ...  -  Apr 18, 2007
Pharmaceutical Business Review...to launch a CD20-inhibiting monoclonal antibody to follow, and build upon, the success shown by Rituxan/MabThera (rituximab) in the RA indication.

New Hope For Lupus Sufferers  -  Apr 17, 2007
Hartford Courant,...trials of a Bristol-Myers Squibb drug called Abatacept, and trials in the United States of Hoffmann-La Roche's CellCept and Genentech's Rituximab.

GSK Initiates Repeat Dosing Study Of Its Novel Oral Platelet ...  -  Apr 16, 2007
Medical News Today (press release),...in patients previously treated for chronic ITP, examples of which includesplenectomy, corticosteroids, immunoglobulins, cyclophosphamide and rituximab.

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic ...  -  Apr 15, 2007
News-Medical.net,...in patients previously treated for chronic ITP, examples of which include splenectomy, corticosteroids, immunoglobulins, cyclophosphamide or rituximab.

Point Therapeutics Announces Preclinical Data Presentations at ...  -  Apr 13, 2007
PharmaLive.com (press release),...in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.

XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes  -  Apr 12, 2007
PipelineReview.com (press release),..."Having participated in the development of other biological drugs such as rituximab, etanercept and anakinra, I can say that I am excited about the

Pain, progress for arthritis sufferer  -  Apr 12, 2007
Indianapolis Star,She started a regimen including rituximab, a chemotherapy drug for Hodgkin's patients. The first series kept her pain-free and comfortable for six months

Genentech Announces First Quarter 2007 Results  -  Apr 12, 2007
PharmaLive.com (press release),...supplemental Biologics License Application (sBLA) seeking to expand the Rituxan(R) (Rituximab) label to include inhibition of progression of structural

Genentech earnings soar but Lucentis sales slow down slightly  -  Apr 12, 2007
Pharma Times (subscription),The arthritis and non-Hodgkin's lymphoma drug Rituxan (rituximab) posted a 12% gain to $535 million, while Xolair (omalizumab) for severe asthma was up 17%

Genentech Announces First Quarter 2007 Results  -  Apr 11, 2007
Business Wire (press release),...a supplemental Biologics License Application (sBLA) seeking to expand the Rituxan® (Rituximab) label to include inhibition of progression of structural

Affimed Raises $33.5M For TandAbs In Oncology  -  Apr 11, 2007
BioWorld Online,Rituxan (rituximab), marketed by Genentech Inc., of South San Francisco, already has attained blockbuster status in that indication.

Nereus Pharmaceuticals to Present Data at the American Association ...  -  Apr 9, 2007
PR Newswire (press release),David Geffen School of Medicine at UCLA, Los Angeles, CA, Nereus Pharmaceuticals, San Diego, CA #1453: Rituximab-mediated sensitization of resistant B-NHL

Pipeline Insight: Multiple Sclerosis - The oral revolution  -  Mar 30, 2007
Pharmaceutical Business ReviewBiogen Idec's Rituxan (rituximab) and BioMS' MBP-8298 are targeting the prevalent yet largely underserved primary progressive MS (PPMS) and secondary

Point Therapeutics Announces Management Change and Additional ...  -  27 Mar 2007
Business Wire (press release),...in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.

Cell Therapeutics, Inc. (CTI) Files For Special Protocol ...  -  Mar 14, 2007
Medical News Today (press release),Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients with relapsed indolent NHL

Cell Therapeutics, Inc. (CTI) Files for Special Protocol ...  -  Mar 13, 2007
PR Newswire (press release),Pixantrone in Indolent NHL Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients

Point Therapeutics Reports Fourth Quarter and Year-End 2006 ...  -  Mar 16, 2007
Business Wire (press release),Grant which funded a portion of Point’s current Phase 2 study combining talabostat with rituximab in advanced chronic lymphocytic leukemia (CLL).

SPA Filed for Pixantrone in NHL  -  Mar 15, 2007
Cancer Consultants (press release),The phase III trial evaluating pixantrone, PIX303, will compare pixantrone/fludarabine/rituximab to fludarabine/rituximab in the treatment of relapsed or

Cell Therapeutics Files For Special Protocol Assessment With FDA ...  -  Mar 13, 2007
Trading Markets,...pixantrone and rituximab compared to the combination of fludarabine and rituximab in the treatment of patients who have failed up to five prior

Market Report -- In Play (CTIC)  -  Mar 13, 2007
MSN MoneyThe trial will examine the complete remission rates and time to disease progression of the combination regimen of fludarabine, pixantrone and rituximab

Eisai acquires US oncology expert Morphotek for $325 million  -  Mar 23, 2007
Pharma Times (subscription),Ontak is also being developed in combination with Johnson & Johnson/Schering-Plough's Rituxan (rituximab) for non-Hodgkin's lymphoma, while Targretin is

CHOP Alone Sufficient for Localized Aggressive Lymphoma in the Elderly  -  Mar 21, 2007
Cancerpage.com,To improve 5-year survival further, it may be advantageous to add rituximab to eight cycles of CHOP, Dr. Fillet and colleagues suggest.

Tracon Licenses D93 Antibody From Micromet  -  Mar 18, 2007
BioWorld Online,...filled the senior management ranks with executives who had contributed to the development of Rituxan (rituximab, Genentech Inc. and Biogen Idec Inc.),

Biotech Day in Review: Glaxo Gets Approval for Tykerb  -  Mar 14, 2007
Seeking Alpha,Pixantrone will be administered as an adjunct to fludarabine and rituximab, and compared to results of a regimen using only the other two drugs.

BMS extends large Lonza deal  -  Mar 13, 2007
In-PharmaTechnologist.com,...direct competition only from Rituxan (rituximab), a cancer drug made by Genentech, which was approved in February last year to treat rheumatoid arthritis.

Point Therapeutics Receives Letter from Nasdaq Citing Non ...  -  Mar 13, 2007
PharmaLive.com (press release),...cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with docetaxel in NSCLC.

Global Market for Cancer Immunotherapy Worth $37.2 Billion by 2012  -  Mar 7, 2007
PharmaLive.com (press release),The three leading monoclonal antibody cancer treatments-Gleevec (imatinib), Herceptin (trastuzumab) and Rituxan (rituximab)-were multibillion dollar drugs

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional